

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: August 9, 2005 <i>(use as many sheets as necessary)</i>				Application Number	10/823,995
				Filing Date	04/14/2004
				First Named Inventor	Paul A. Renhowe
				Group Art Unit	1625
				Examiner Name	Z. N. Davis
Sheet	1	of	2	Attorney Docket Number	072121-0389

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
gnd		Zetter, B. R., "Angiogenesis and Tumor Metastasis," Annu. Rev. Med., 1998, Vol. 49, pp. 407-24; published by Annual Review Inc.	
gnd		MSNBC News Services, "Mixed results on new cancer drug," November 9, 2000.	
gnd		Gura, T., "Systems for Identifying New Drugs Are Often Faulty," Science, 1997, Vol. 278, pp. 1041-1042.	

Examiner Signature	Z. N. Davis	Date Considered	3/3/2006
--------------------	-------------	-----------------	----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: August 9, 2005 (use as many sheets as necessary)		Application Number	10/823,995
		Filing Date	04/14/2004
		First Named Inventor	Paul A. Renhowe
		Group Art Unit	1623
		Examiner Name	2NDAVIS
Sheet	2	of	2
		Attorney Docket Number	072121-0389


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		Dermer, G. B., "Another Anniversary for the War on Cancer," <i>Biotechnology</i> , 1994, Vol. 12, p. 320.	
		Freshney, R. I., <i>Culture of Animal Cells - A Manual of Basic Technique</i> , 1983, pp. 1-4; published by Alan R. Liss, Inc.	
		Angiogenesis Foundation, "New Study Shows That Acute Myeloid Leukemia is Angiogenesis-Dependent," January 4, 2000; www.angio.org/newsandviews/archive2000/jan_4_2000.html .	
		Hussong, J. W. <i>et al.</i> , "Evidence of increased angiogenesis in acute myeloid leukemia," <i>Blood</i> , 2000, Vol. 95(1), pp. 309-313; The American Society of Hematology.	
		Kerbel, R. S., "Tumor Angiogenesis: Past, Present and Near Future," <i>Carcinogenesis</i> , 2000, Vol. 21(3), pp. 505-515; Oxford University Press.	
		Lundberg, L. G. <i>et al.</i> , "Bone Marrow in Polycythemia Vera, Chronic Myelocytic Leukemia, and Myelofibrosis Has an Increased Vascularity," <i>American Journal of Pathology</i> , 2000, Vol. 157(1), pp. 15-19.	
		Dankbar, B. <i>et al.</i> , "Vascular endothelial growth factor and interleukin-8 in paracrine tumor-stromal cell interactions in multiple myeloma," <i>Blood</i> , 2000, Vol. 5(8), pp. 2630-2636.	
		Menzel, T. <i>et al.</i> , "Elevated Intracellular Level of Basic Fibroblast Growth Factor Correlates with Stage of Chronic Lymphocytic Leukemia and is Associated With Resistance to Fludarabine," <i>Blood</i> , 1996, Vol. 87(3), pp. 1056-1063.	
		Gruber, G. <i>et al.</i> , "Basic Fibroblast Growth Factor is Expressed in CD19/CD11c-Positive Cells in Hairy Cell Leukemia," <i>Blood</i> , 1999, Vol. 94(3), pp. 1077-1085.	

Examiner Signature		Date Considered	3/3/2006
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PATENT INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: January 12, 2006 (use as many sheets as necessary)				Complete If Known	
				Application Number	10/823,995
				Filing Date	04/14/2004
				First Named Inventor	Paul A. Renhowe
				Group Art Unit	1614-1625
				Examiner Name	ZND/AVS
				Attorney Docket Number	072121-0389 (16325.009)
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
ZND			WO 00/00481	/	Du Pont Pharmaceuticals Company	1/6/2000		
			WO 02/22598	/	Chiron Corporation	3/21/2002		
			WO 03/087095	/	Chiron Corporation	10/23/2003		
			WO 2004/018419	/	Chiron Corporation	3/4/2004		
			WO 2004/030620	/	Bristol-Myers Squibb Co.	4/15/2004		
			WO 2004/043389	/	Chiron Corporation	5/27/2004		
			WO 2004/087153	/	Chiron Corporation	10/14/2004		
			WO 2005/046589	/	Chiron Corporation	5/26/2005		
ZND			WO 2005/053692	/	The Scripps Research Institute	6/16/2005		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
ZND		International Search Report for PCT/US2005/005316 dated November 28, 2005.	

Examiner Signature	ZND/AVS	Date Considered	5/3/2006
--------------------	---------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 072121-0389		SERIAL NO. 10/823,995		
INFORMATION DISCLOSURE CITATION Date filed: April 14, 2004 (Use several sheets if necessary)				APPLICANT Paul A. Renhowe et al.				
				FILING DATE Submitted Herewith		GROUP ART UNIT 1625 <i>Unknown</i>		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
<i>Handwritten:</i> ↑ ↓		4,882,342	Nov. 21, 1989	Von der Saal et al.				
		5,073,492	Dec. 17, 1991	Chen et al.				
		5,414,088	May 9, 1995	Von der Saal et al.				
		5,585,380	Dec. 17, 1996	Bianco et al.				
		5,646,153	Jul. 8, 1997	Spada et al.				
		5,710,158	Jan. 20, 1998	Myers et al.				
<i>Handwritten:</i> ↓		5,763,441	Jun. 9, 1998	App et al.				
FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
<i>Handwritten:</i> ↑ ↓		2363459	Jun. 26, 1975	Germany				
		DE 3634066 A1	July 10, 1986	Germany				
		19841985	Mar. 9, 2000	Germany				
<i>Handwritten:</i> ↓		0 290 153	Nov. 9, 1998	Europe				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
<i>Handwritten:</i> ↑ ↓		Aprelikova, O., et al., "FLT4, a novel Class III Receptor Tyrosine Kinase in chromosome 5q33-qter1," <i>Cancer Res.</i> , Vol. 52, pp. 746-748, February 1, 1992, published by The American Association for Cancer Research, Stanford University Libraries' High Wire Press, California, United States of America.						
		Carmeliet, P. et al., "Angiogenesis in Cancer and Other Diseases," <i>Nature</i> , 407, pp. 249-257 (2000).						
		Connolly, D., et al., "Human Vascular Permeability Factor," <i>J. Biol. Chem.</i> , Vol. 264, pp. 20017-20024, 1989, published by The American Society For Biochemistry and Molecular Biology, Inc., Stanford University Libraries' High Wire Press, California, United States of America.						
		Connolly, D., et al., "Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis," <i>J. Clin. Invest.</i> , Vol. 84, pp. 1470-1478, November, 1989, published by The American Society for Clinical Investigation, Inc., Stanford University Libraries' High Wire Press, California, United States of America.						
<i>Handwritten:</i> ↓		DeVries, C., et al., "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <i>Science</i> , Vol. 255, pp. 989-991, February 21, 1992, published by The American Society for the Advancement of Science, Stanford University Libraries' High Wire Press, California, United States of America.						
EXAMINER <i>Linne W Davis</i>				DATE CONSIDERED <i>3/3/2006</i>				
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.								

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 072121-0389		SERIAL NO. 01823,995		
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Paul A. Renhowe et al.				
				FILING DATE Submitted Herewith		GROUP ART UNIT Unknown 1625		
FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
01823,995		0 509 717	Apr. 10, 1992	Europe				
		0 508 800	Oct. 14, 1992	Europe				
		0 747 771	Dec. 11, 1996	Europe				
		0 797 376	Sep. 24, 1997	Europe				
		1 086 705	Mar. 28, 2001	Europe				
		6-9952	Jan. 18, 1994	Japan				
		7-43896	Feb. 14, 1995	Japan				
		8-29973	Feb. 2, 1996	Japan				
		63-258903	Oct. 26, 1998	Japan				
		92/18483	Oct. 29, 1992	WO				
		92/20642	Nov. 26, 1992	WO				
		95/15758	Jun. 15, 1995	WO				
		95/18801	Jul. 13, 1995	WO				
		97/03069	Jan. 30, 1997	WO				
		97/34876	Sep. 25, 1997	WO				
		97/48694	Dec. 24, 1997	WO				
		98/13350	Apr. 2, 1998	WO				
		99/10349	Mar. 4, 1999	WO				
		99/50263	Oct. 7, 1999	WO				
		99/65897	Dec. 23, 1999	WO				
	00/27379	May 18, 2000	WO					
	01/02369	Jan. 11, 2001	WO					
	01/29025	Apr. 26, 2001	WO					
	01/28993	Apr. 26, 2001	WO					
	01/52904	Jul. 26, 2001	WO					
	01/55114	Aug. 2, 2001	WO					
	01/62251	Aug. 30, 2001	WO					
	01/62252	Aug. 30, 2001	WO					
01823,995		02/32861	Apr. 25, 2002	WO				

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 072121-0389	SERIAL NO. 10/823,995
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Paul A. Renhowe et al.	
		FILING DATE Submitted Herewith	GROUP ART UNIT Unknown 1625
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
1st		Ferrara, N., et al., "The Biology of Vascular Endothelial Growth Factor," <i>Endocrinol. Rev.</i> , Vol. 18, No. 1, pp. 4-25, 1997, published by The Endocrine Society, Stanford University Libraries' High Wire Press, California, United States of America.	
		Folkman, J., "Fighting Cancer by Attacking Its Blood Supply," <i>Scientific American</i> , Vol. 275, pp. 150-154, September, 1996, published by Scientific American, Inc., New York, New York, United States of America.	
		Hennequin, L. F., et al., "Design and Structure - Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors," <i>J. Med. Chem.</i> , Vol. 42, No. 26, pp. 5369-5389, 1999; published by American Chemical Society, Washington, D.C.	
		Leung, D., et al., "Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen," <i>Science</i> , Vol. 246, pp. 1306-1309, December 8, 1989, published by The American Society for the Advancement of Science, Stanford University Libraries' High Wire Press, California, United States of America.	
		Lymboussaki, A., "Vascular endothelial growth factors and their receptors in embryos, adults, and in tumors," Academic Dissertation, University of Helsinki, Molecular/Cancer Biology Laboratory and Department of Pathology, Haartman Institute, 1999.	
		Maguire, M.P., et al., "A New Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Substituted Quinoline Derivatives," <i>J. Med. Chem.</i> , Vol. 37, No. 14, pp. 2129-2137, 1994; published by American Chemical Society, Washington, D.C.	
		Matei, S., et al., "Condensation of ethyl 2-benzimidazoleacetate with carbonyl compounds," <i>Rev. Chim.</i> , Vol. 33, No. 6, pp. 527-530, 1989, published by the Central Institute of Chemistry, Bucharest, Romania.	
		Mustonen, T., et al., "Endothelial Receptor Tyrosine Kinases Involved in Angiogenesis," <i>J. Cell Biology</i> , Vol. 129, No. 4, pp. 895-898, May, 1995, published by The Rockefeller University Press, New York, New York, United States of America.	
		Plouet, J., et al., "Isolation and characterization of a newly identified endothelial cell mitogen produced by AIT-20 cells," <i>EMBO J.</i> , Vol. 8, No. 12, pp. 3801-3806, 1989, published by IRL Press.	
		Quinn, T., et al., "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pp. 7533-7537, August, 1993.	
		Shibuya, M., et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family," <i>Oncogene</i> , Vol. 5, pp. 519-524, 1990, published by Macmillan Press Ltd., Stockton Press Company, Great Britain.	
		Stover, D. R., "Recent advances in protein kinase inhibition: Current molecular scaffolds used for inhibitor synthesis," <i>Current Opinion in Drug Discovery & Development</i> , Vol. 2, No. 4, pp. 274-285, 1999; published by PharmaPress Ltd., London, United Kingdom.	
		Terman, B., et al., "Identification of a new endothelial cell growth factor receptor tyrosine kinase," <i>Oncogene</i> , Vol. 6, pp. 1677-1683, 1991, published by Macmillan Press Ltd., Stockton Press Company, Great Britain.	
		Ukrainets, I., "Effective Synthesis of 3-(Benzimidazol-2-yl)-4-Hydroxy-2-Oxo-1,2-Dihydroquinolines," <i>Tet. Lett.</i> , Vol. 36, No. 42, pp. 7747-7748, 1995, published by Elsevier Science Ltd., Great Britain.	
		Ukrainets, I., et al., "2-Carboethoxymethyl-4H-3,1-Benzoxazin-4-One. 3." "Condensation of o-Phenylenediamine," pp. 198-200, translated from <i>Khimiya Geterotsiklicheskikh Soedinii</i> , No. 2, pp. 239-241, February, 1992, published by Plenum Publ. Corp., London, Great Britain.	

[illegible]



Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 072121-0389	SERIAL NO. 10/823,995
INFORMATION DISCLOSURE CITATION Date Submitted: January 12, 2005 (Use several sheets if necessary)		APPLICANT Renhowe et al.	
		FILING DATE 04/14/2004	GROUP ART UNIT Unknown <i>2/11/05</i>

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>Spnd</i>		Salmon, S. E. et al., <i>Basic & Clinical Pharmacology, Seventh Edition</i> , edited by B. Katzung, Appleton & Lange, pp. 29, 881-884 (1998).
<i>Spnd</i>		Milauer, B. et al., "Glioblastoma Growth Inhibited In Vivo by a Dominant-Negative Flk-1 Mutant," <i>Nature</i> , Vol. 367, pp. 576-579 (1994); published by Nature Publishing Group.
<i>Spnd</i>		Pinedo, H. M. et al., "Translational Research: The Role of VEGF in Tumor Angiogenesis," <i>The Oncologist</i> 2000, Vol. 5 (suppl. 1), pp. 1-2 (2000).
<i>Spnd</i>		McMahon, G., "VEGF Receptor Signaling in Tumor Angiogenesis," <i>The Oncologist</i> 2000, Vol. 5 (suppl. 1), pp. 3-10 (2000).

EXAMINER <i>Lina N. Davis</i>	DATE CONSIDERED <i>3/3/2006</i>
----------------------------------	------------------------------------

- * EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.